Healthcare Services

Macular Degeneration Treatment Market Growth Outlook Indicating Expansion To $20.74 Billion By 2030

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Macular Degeneration Treatment Market During The 2026–2030 Period?

The macular degeneration treatment market size has seen significant expansion in recent years. It is projected to grow from $12.38 billion in 2025 to $13.81 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.5%. The market’s past growth can be attributed to factors such as an aging global population, an increased prevalence of age-related macular degeneration, the clinical success of anti-VEGF injections, improved ophthalmic diagnostic capabilities, and growing access to specialized eye care services.

The macular degeneration treatment market is projected to experience swift expansion in the coming years. This market is forecast to reach $20.74 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth during the projection period include a globally increasing elderly population, greater investment in sophisticated retinal treatments, an intensified focus on managing early-stage AMD, wider embrace of gene and regenerative therapies, and elevated healthcare expenditure on vision-related care. Key trends anticipated for the forecast timeframe encompass an increased emphasis on early diagnosis and managing disease progression, wider uptake of anti-VEGF therapies, a rising need for treatments aimed at long-term vision preservation, the proliferation of minimally invasive treatment choices, and enhanced public awareness regarding age-related eye conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

What Important Drivers Are Powering The Macular Degeneration Treatment Market Growth?

The rising prevalence of retinal disorders is anticipated to propel the growth of the macular degeneration treatment market. These conditions affect vital tissue, disrupting how individuals process visual information and leading to distorted or absent vision. For instance, according to the American Academy of Ophthalmology, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, a general term used to describe a group of eye disorders, by 2050, with the highest numbers observed among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

Which Segment Groups Define The Macular Degeneration Treatment Market Landscape?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By Route of Administration: Oral, Injectable, Other Routes of Administration

3) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Regular Disease Monitoring and Imaging Surveillance, Risk-Factor Management and Lifestyle Modification

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

Which Trends Are Expected To Shape The Macular Degeneration Treatment Market?

Leading companies in the macular degeneration treatment market are concentrating on developing biosimilar medications for age-related macular degeneration (AMD) to broaden access to effective therapeutic options. Biosimilars are biological medical products that bear a high degree of resemblance to an already approved reference product, lacking any clinically relevant distinctions in terms of their safety, purity, or potency. For instance, in May 2024, Biocon Biologics Ltd, an Indian-based company, and Samsung Bioepis Co. Ltd, a South Korea-based company, obtained FDA Approvals for Yesafili and Opuviz, which are two novel biosimilars. Both of these biosimilars work by inhibiting vascular endothelial growth factor (VEGF), a factor responsible for abnormal blood vessel proliferation within the eye. This mechanism assists in preventing vision loss linked to conditions like AMD and diabetic retinopathy. The FDA’s approval process encompassed comparative studies that indicated Yesafili and Opuviz possess no notable differences in their efficacy or safety when compared to Eylea. These investigations involved thorough evaluations of the biosimilars’ pharmacokinetics and immunogenicity.

Which Firms Are Competing In The Macular Degeneration Treatment Market?

Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc

Access The Complete Macular Degeneration Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Which Region Stands As The Largest Contributor To The Macular Degeneration Treatment Market?

North America was the largest region in the macular degeneration treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Macular Degeneration Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

Browse Through More Reports Similar to the Global Macular Degeneration Treatment Market 2026, By The Business Research Company

Antibiotics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Peptide Antibiotics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Veterinary Antibiotics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795